AR064154A1 - Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas - Google Patents

Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas

Info

Publication number
AR064154A1
AR064154A1 ARP070105448A ARP070105448A AR064154A1 AR 064154 A1 AR064154 A1 AR 064154A1 AR P070105448 A ARP070105448 A AR P070105448A AR P070105448 A ARP070105448 A AR P070105448A AR 064154 A1 AR064154 A1 AR 064154A1
Authority
AR
Argentina
Prior art keywords
cr14r15
nr10r11
alkyl
nr12c
optionally substituted
Prior art date
Application number
ARP070105448A
Other languages
English (en)
Original Assignee
Piramed Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39403189&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064154(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Piramed Ltd, Genentech Inc filed Critical Piramed Ltd
Publication of AR064154A1 publication Critical patent/AR064154A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Estos compuestos son utiles para modular la actividad de las quinasas lipídicas, incluyendo PI3K, y para tratar trastornos tales como cáncer mediados por las quinasas lipídicas. Se revelan composiciones farmacéuticas y uso del compuesto para preparar medicamentos. Reivindicacion 1: Un compuesto seleccionado de la formula 1c y la formula 1d, y sus estereoisomeros, isomeros geométricos, tautomeros, solvatos, metabolitos y sales aceptables desde el punto de vista farmacéutico, en los cuales: X es O o S; R1 se selecciona de H, F, CI, Br, I, -C(alquil C1-6)2NR10R11, -(CR14R15)tNR10R11, -C(R14R15)nNR12C(=Y)R10, -(CR14R15)nNR12S(O)2R10, -CH(OR10)R10, -(CR14R15)nOR10, -(CR14R15)nS(O)2R10, -(CR14R15)nS(O)2NR10R11, -C(=Y)R10, - C(=Y)OR10, -C(=Y)NR10R11, -C(=Y)NR12OR10, -C(=O)NR12S(O)2R10, -C(=O)NR12(CR14R15)mNR10R11, -NO2, -NHR12, -NR12C(=Y)R11, -NR12C(=Y)OR11, -NR12C(=Y)NR10R11, -NR12S(O)2R10, -NR12SO2NR10R11, -S(O)2R10, -S(O)2NR10R11, -SC(=Y)R10, -SC(=Y)OR10, alquilo C1- 12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20; R2 se selecciona de H, F, CI, Br, I, arilo C6-20, heteroarilo C1-20, alquilo C1-6, alquenilo C2-8 y alquinilo C2-8; R3 es un grupo heteroarilo monocíclico seleccionado de piridilo, isoxazolilo, imidazolilo, pirazolilo, pirrolilo, tiazolilo, piridazinilo, pirimidinilo, pirazinilo, oxazolilo, furanilo, tienilo, triazolilo, tetrazolilo, donde el grupo heteroarilo monociclico está sustituido en forma opcional con uno o más grupos seleccionados de F, CI, Br, I, -CN, -NR10R11, -OR10, -C(O)R10, -NR10C(O)R11, -N(C(O)R11)2, -NR10C(O)NR10R11, -C(=O)OR10, -C(=O)NR10R11, alquilo C1-C12, y alquil C1-12-OR10; R10, R11 y R12 son en forma independiente H, alquilo C1-C12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, o heteroarilo C1-20, o R10 y R11 junto con el nitrogeno al cual están unidos en forma opcional forman un anillo heterocíclico C3-20 que contiene en forma opcional uno o más átomos adicionales en el anillo seleccionados de N, O o S, donde dicho anillo heterocíclico está sustituido en forma opcional con uno o más grupos seleccionados en forma independiente de oxo, (CH2)nOR10, NR10R11, CF3, F, CI, Br, I, SO2R10, C(=O)R10, NR12C(=Y)R11, C(=Y)NR10R11, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20, y heteroarilo C1-20; R14 y R15 se seleccionan en forma independiente de H, alquilo C1-12 o -(CH2)n-arilo, o R14 y R15 junto con los átomos a los cuales están unidos forman un anillo carbocíclico C3-12 saturado o parcialmente insaturado, mor es un grupo morfolino sustituido en forma opcional con uno o más grupos seleccionados de F, CI, Br, I, -C(alquil C1-6)2NR10R11, -(CR14R15)tNR10R11, -C(R14R15)nNR12C(=Y)R10, -(CR14R15)nNR12S(O)2R10, -CH(OR10)R10, -(CR14R15)nOR10, -(CR14R15)nS(O)2R10, -(CR14R15)nS(O)2NR10R11, -C(=Y)R10, -C(=Y)OR10, - C(=Y)NR10R11, -C(=Y)NR12OR10, -C(=O)NR12S(O)2R10, -C(=O)NR12(CR14R15)mNR10R11, -NO2, -NHR12, -NR12C(=Y)R11, -NR12C(=Y)OR11, -NR12C(=Y)NR10R11, -NR12S(O)2R10, -NR12SO2NR10R11, -S(O)2R10, -S(O)2NR10R11, -SC(=Y)R10, -SC(=Y)OR10, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20; donde dichos alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo y heteroarilo están sustituidos en forma opcional con uno o más grupos seleccionados en forma independiente de F, CI, Br, I, -CN, CF3, -NO2, oxo,-C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -(CR14R15)nNR10R11, -(CR14R15)nNR12SO2R10, -(CR14R15)nOR10, -NR10R11, -NR12C(=Y)R10, -NR12C(=Y)OR11, -NR12C(=Y)NR10R11, - NR12SO2R10, =NR12, OR10, OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, -OS(O)2(OR10), -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), SR10, -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -S(O)(OR10), -S(O)2(OR10), -SC(=Y)R10, SC(=Y)OR10, -SC(=Y)NR10R11, alquilo C1-12 sustituido en forma opcional, alquenilo C2-8 sustituido en forma opcional, alquinilo C2-8 sustituido en forma opcional, carbociclilo C3-12 sustituido en forma opcional, heterociclilo C2-20 sustituido en forma opcional, arilo C6-20 sustituido en forma opcional, y heteroarilo C1-20 sustituido en forma opcional; Y es O, S o NR12; m es 0, 1, 2, 3, 4, 5 o 6; n es 1, 2, 3, 4, 5 o 6; y t es 2, 3, 4, 5 o 6.
ARP070105448A 2006-12-07 2007-12-05 Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas AR064154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87342206P 2006-12-07 2006-12-07

Publications (1)

Publication Number Publication Date
AR064154A1 true AR064154A1 (es) 2009-03-18

Family

ID=39403189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105448A AR064154A1 (es) 2006-12-07 2007-12-05 Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas

Country Status (19)

Country Link
US (1) US9487533B2 (es)
EP (1) EP2114950B1 (es)
JP (1) JP5500990B2 (es)
KR (1) KR101507182B1 (es)
CN (1) CN101675053B (es)
AR (1) AR064154A1 (es)
AU (1) AU2007333243B2 (es)
BR (1) BRPI0717907A2 (es)
CA (1) CA2671845C (es)
CL (1) CL2007003523A1 (es)
ES (1) ES2571028T3 (es)
IL (1) IL199151A (es)
MX (1) MX2009005925A (es)
NO (1) NO342697B1 (es)
PE (1) PE20081353A1 (es)
RU (1) RU2470936C2 (es)
TW (1) TW200829594A (es)
WO (1) WO2008073785A2 (es)
ZA (1) ZA200904531B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE448532T1 (de) * 1996-09-04 2009-11-15 Intertrust Tech Corp Zuverlässige infrastrukturhilfssysteme, verfahren und techniken für sicheren elektronischen handel, elektronische transaktionen, handelsablaufsteuerung und automatisierung, verteilte verarbeitung und rechteverwaltung
ES2544082T3 (es) * 2006-12-07 2015-08-27 F. Hoffmann-La Roche Ag Compuestos inhibidores de fosfoinosítido 3-quinasa y métodos de uso
EP2158207B1 (en) * 2007-06-12 2011-05-25 F. Hoffmann-La Roche AG Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
EP2205242B1 (en) * 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042607A1 (en) 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
WO2009055730A1 (en) * 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
ES2432821T3 (es) * 2008-07-31 2013-12-05 Genentech, Inc. Compuestos de pirimidina, composiciones y métodos de utilización
WO2010027002A1 (ja) * 2008-09-05 2010-03-11 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する縮環モルホリン誘導体
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
US9181182B2 (en) 2008-10-17 2015-11-10 Akaal Pharma Pty Ltd S1P receptors modulators
CA2740484C (en) 2008-10-17 2021-09-21 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
MX2011007326A (es) 2009-01-08 2011-10-19 Curis Inc Inhibidores de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
EP2405916B1 (en) * 2009-03-12 2018-02-07 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
EP2405973B1 (en) * 2009-03-13 2015-04-22 Katholieke Universiteit Leuven, K.U. Leuven R&D Thiazolopyrimidine modulators as immunosuppressive agents
SG172951A1 (en) 2009-03-24 2011-08-29 Sumitomo Chemical Co Method for manufacturing a boronic acid ester compound
WO2010136491A1 (en) * 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
BRPI1009022A2 (pt) * 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
LT2496567T (lt) 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
US8288381B2 (en) * 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
CA2780018C (en) * 2009-11-12 2015-10-20 F. Hoffmann-La Roche Ag N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
BR112012019635A2 (pt) 2010-02-22 2016-05-03 Hoffmann La Roche compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
SG186378A1 (en) * 2010-06-23 2013-01-30 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2012007493A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for ρi3κ p110 delta, and methods of use
DE102010049595A1 (de) * 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
SI2651951T1 (sl) 2010-12-16 2015-01-30 F. Hoffmann-La Roche Ag Tricikliäśne p13k inhibitorske spojine in postopki uporabe
JP2014505076A (ja) * 2011-01-27 2014-02-27 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス剤としてのｍＴＯＲキナーゼの阻害剤
CN103476767B (zh) 2011-02-09 2015-06-10 弗·哈夫曼-拉罗切有限公司 作为pi3激酶抑制剂的杂环化合物
CN103501610A (zh) * 2011-03-09 2014-01-08 西建阿维拉米斯研究公司 Pi3激酶抑制剂和其用途
BR112013024122A2 (pt) 2011-03-21 2019-09-24 Hoffmann La Roche compostos de benzoxazepina seletivos para p110 delta pi3k e métodos de uso
PL2694075T3 (pl) 2011-04-01 2016-09-30 Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk
LT2694484T (lt) 2011-04-08 2018-10-10 Janssen Sciences Ireland Uc Pirimidino dariniai, skirti virusinių infekcijų gydymui
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
RS57851B1 (sr) 2011-11-09 2018-12-31 Janssen Sciences Ireland Uc Purinski derivati za tretman viralnih infekcija
CN104053661B (zh) 2011-11-23 2018-06-19 癌症研究技术有限公司 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂
CN103467482B (zh) 2012-04-10 2017-05-10 上海璎黎药业有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
EP2852661A1 (en) 2012-05-23 2015-04-01 F. Hoffmann-La Roche AG Compositions and methods of obtaining and using endoderm and hepatocyte cells
SG10201706196XA (en) 2012-06-08 2017-08-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
KR102216606B1 (ko) 2012-07-04 2021-02-17 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
ES2590508T3 (es) 2012-07-13 2016-11-22 Janssen Sciences Ireland Uc Purinas macrocíclicas para el tratamiento de infecciones víricas
CN104837840B (zh) 2012-10-10 2017-08-08 爱尔兰詹森科学公司 用于治疗病毒感染及其他疾病的吡咯并[3，2‑d]嘧啶衍生物
ES2594078T3 (es) * 2012-10-10 2016-12-15 F. Hoffmann-La Roche Ag Proceso para preparar compuestos de tienopirimidina
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
EA035431B1 (ru) 2012-11-16 2020-06-15 Янссен Сайенсиз Айрлэнд Юси Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций
AU2014220717B2 (en) 2013-02-21 2018-03-29 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
HUE031908T2 (en) 2013-03-29 2017-08-28 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
US10377738B2 (en) 2013-05-24 2019-08-13 Janssen Sciences Ireland Unlimited Company Pyridone derivatives for the treatment of viral infections and further diseases
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
DK3030563T3 (da) 2013-06-27 2017-11-20 Janssen Sciences Ireland Uc Pyrrolo-[3,2-d]-pyrimidin-derivater til behandling af virale infektioner og andre sygdomme
MY179503A (en) * 2013-07-30 2020-11-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
CN104513254B (zh) 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR102343802B1 (ko) * 2014-06-09 2021-12-28 수미토모 케미칼 컴퍼니 리미티드 피리딘 화합물의 제조 방법
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
KR20160082062A (ko) 2014-12-30 2016-07-08 한미약품 주식회사 싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
JP6698712B2 (ja) 2015-06-29 2020-05-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｔａｓｅｌｉｓｉｂを用いた治療方法
CN106467545B (zh) * 2015-08-20 2018-10-16 北大方正集团有限公司 一种噻吩并嘧啶化合物
SG11201804901WA (en) * 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2018001952A1 (en) * 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection
JP7171444B2 (ja) 2016-07-01 2022-11-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染治療用のジヒドロピラノピリミジン
EP3519406B1 (en) 2016-09-29 2022-02-23 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
EP3573992B1 (en) 2017-01-26 2022-04-13 Youla S. Tsantrizos Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
EA202190748A1 (ru) 2018-09-11 2021-07-22 Кьюрис Инк. Комбинированная терапия ингибитором фосфоинозитид-3-киназы с цинк-связывающей группировкой
CN109540859B (zh) * 2018-11-27 2021-02-09 上海交通大学 一种水体中抗生素的分析和含量预测方法
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
WO2022152229A1 (zh) * 2021-01-15 2022-07-21 深圳微芯生物科技股份有限公司 一类吗啉衍生物及其制备方法和应用
CN116262758A (zh) * 2021-12-15 2023-06-16 上海博悦生物科技有限公司 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途
CN114539293B (zh) * 2022-02-24 2023-09-22 广东晨康生物科技有限公司 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
DE2050814A1 (de) 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen
DE1959403A1 (de) 1969-11-26 1971-06-03 Thomae Gmbh Dr K Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2058085A1 (de) * 1970-11-26 1972-05-31 Thomae Gmbh Dr K Neues Verfahren zur Herstellung von 4-Morpholino-thieno[3,2-d]pyrimidinen
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (es) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
RU1391052C (ru) * 1986-08-25 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 5-формилтиено [2,3-D]пиримидина, обладающие противогерпетической активностью
US5075305A (en) 1991-03-18 1991-12-24 Warner-Lambert Company Compound, composition and use
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
DE60144322D1 (de) 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JPWO2002026745A1 (ja) * 2000-09-29 2004-02-05 日本曹達株式会社 チエノピリミジン化合物とその塩並びに製造方法
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP5058789B2 (ja) * 2004-06-03 2012-10-24 ノードソン コーポレーション 粉体コーティング材料塗布システムの色切り替え
CA2583259C (en) 2004-10-08 2011-08-02 Astellas Pharma Inc. Aromatic ring fused pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2007122410A1 (en) 2006-04-26 2007-11-01 F.Hoffmann-La Roche Ag Pyrimidine derivatives as pi3k inhibitors
RU2439074C2 (ru) 2006-04-26 2012-01-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
MX2008013583A (es) 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
KR101422301B1 (ko) 2006-04-26 2014-07-30 에프. 호프만-라 로슈 아게 약학적 화합물
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
ES2544082T3 (es) 2006-12-07 2015-08-27 F. Hoffmann-La Roche Ag Compuestos inhibidores de fosfoinosítido 3-quinasa y métodos de uso

Also Published As

Publication number Publication date
AU2007333243A1 (en) 2008-06-19
US20080269210A1 (en) 2008-10-30
CA2671845A1 (en) 2008-06-19
ZA200904531B (en) 2010-09-29
EP2114950B1 (en) 2016-03-09
KR101507182B1 (ko) 2015-03-30
EP2114950A2 (en) 2009-11-11
TW200829594A (en) 2008-07-16
AU2007333243B2 (en) 2013-03-14
JP5500990B2 (ja) 2014-05-21
JP2010512337A (ja) 2010-04-22
CL2007003523A1 (es) 2008-08-22
NO20092565L (no) 2009-09-07
IL199151A (en) 2017-01-31
WO2008073785A2 (en) 2008-06-19
PE20081353A1 (es) 2008-11-12
NO342697B1 (no) 2018-07-09
CN101675053B (zh) 2014-03-12
MX2009005925A (es) 2009-08-12
BRPI0717907A2 (pt) 2013-11-05
WO2008073785A3 (en) 2008-08-28
RU2009125916A (ru) 2011-01-20
ES2571028T3 (es) 2016-05-23
US9487533B2 (en) 2016-11-08
KR20090106508A (ko) 2009-10-09
CA2671845C (en) 2015-03-24
CN101675053A (zh) 2010-03-17
IL199151A0 (en) 2010-03-28
RU2470936C2 (ru) 2012-12-27

Similar Documents

Publication Publication Date Title
AR064154A1 (es) Compuestos inhibidores de fodfoinostida 3- quinasas y composiciones farmaceuticas
AR064155A1 (es) Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
AR068402A1 (es) Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
HRP20192336T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
AR060632A1 (es) Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
JP2016530262A5 (es)
ES2855732T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
AR076984A1 (es) Derivados de pirazol oxadiazol
AR077507A1 (es) Derivados de naftiridina-1-ona y composiciones farmaceuticas que los comprenden como inhibidores de cinasa syk
AR067093A1 (es) N-(2-(hetaril) arilsulfonamidas y n-(2-( heteraril) hetaril) arilsulfonamidas
RU2018112252A (ru) Конденсированное пиримидиновое соединение или его соль
RS54358B1 (en) PYROLOPYRIDINES AS KINASE INHIBITORS
AR078187A1 (es) Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
CO6140024A2 (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer
AR079199A1 (es) Composiciones farmaceuticas que comprenden ligandos de receptores sigma
AR076922A1 (es) Benzodiazepinas como inhibidores de pi3k/mtor, una composicion farmaceutica que las comprende, metodos para su fabricacion y su uso en el tratamiento del cancer.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
AR082109A1 (es) Derivados de bipiridilo
AR076187A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos y composicion farmaceutica que los contienen
JP2019521097A5 (es)
AR054625A1 (es) Compuestos de oxazolidinona,procedimiento para prepararlos,composiciones farmaceuticas que los contienen,y uso como agentes antimicrobianos.
RU2015140387A (ru) Пиридопиримидиновое или пиримидопиримидиновое соединение, способ получения, фармацевтическая композиция и применение указанных соединений

Legal Events

Date Code Title Description
FB Suspension of granting procedure